A placebo-controlled trial of buspirone for the treatment of marijuana dependence

TitleA placebo-controlled trial of buspirone for the treatment of marijuana dependence
Publication TypeJournal Article
Year of Publication2009
AuthorsMcRae-Clark, AL, Carter, RE, Killeen, TK, Carpenter, MJ, Wahlquist, AE, Simpson, SA, Brady, KT
JournalDrug and Alcohol Dependence
Date PublishedNov 1
Publication Languageeng
ISBN Number1879-0046 (Electronic)0376-8716 (Linking)
Accession Number19699593
KeywordsAdult, Anti-Anxiety Agents/adverse effects/*therapeutic use, Anxiety/drug therapy/etiology/psychology, Buspirone/adverse effects/*therapeutic use, Cannabinoids/urine, Cannabis/adverse effects, Double-Blind Method, Female, Humans, Male, Marijuana Abuse/*drug therapy/psychology/urine, Motivation, Psychiatric Status Rating Scales, Questionnaires, Sample Size, Substance Withdrawal Syndrome/epidemiology/psychology, Treatment Outcome

The present study investigated the potential efficacy of buspirone for treating marijuana dependence. Participants received either buspirone (maximum 60mg/day) (n=23) or matching placebo (n=27) for 12 weeks, each in conjunction with motivational interviewing. In the modified intention-to-treat analysis, the percentage of negative UDS results in the buspirone-treatment group was 18 percentage points higher than the placebo-treatment group (95% CI: -2% to 37%, p=0.071). On self-report, participants receiving buspirone reported not using marijuana 45.2% of days and participants receiving placebo reported not using 51.4% of days (p=0.55). An analysis of participants that completed the 12-week trial showed a significant difference in the percentage negative UDS (95% CI: 7-63%, p=0.014) and a trend for participants randomized to the buspirone-treatment group who completed treatment to achieve the first negative UDS result sooner than those participants treated with placebo (p=0.054). Further study with buspirone in this population may be warranted; however, strategies to enhance study retention and improve outcome measurement should be considered in future trials.

Go to top